Abstract
A dose-escalation study was conducted for patients with inoperable or recurrent breast cancer in order to determine the recommended dose (RD) of capecitabine combined with a fixed dose of weekly paclitaxel. Capecitabine was administered twice daily from day 1 through day 14 combined with paclitaxel given on days 1 and 8, every 21 days. Dose-limiting toxicities(DLT)were evaluated during the first two cycles. Three patients were recruited at one of two dose levels (capecitabine 1,255 mg/m2 or 1,657 mg/m2, paclitaxel 80 mg/m2). In this study, no DLT was seen in each level, and the RD of capecitabine was determined to be 1,657 mg/m2.
Publication types
-
Clinical Trial, Phase I
-
English Abstract
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Capecitabine
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Dose-Response Relationship, Drug
-
Female
-
Fluorouracil / adverse effects
-
Fluorouracil / analogs & derivatives*
-
Fluorouracil / therapeutic use
-
Humans
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*
-
Paclitaxel / adverse effects
-
Paclitaxel / therapeutic use*
Substances
-
Deoxycytidine
-
Capecitabine
-
Paclitaxel
-
Fluorouracil